We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Antares Pharma, Inc. (“Antares” or the “Company”) (NASDAQ: ATRS), in connection with the proposed acquisition of the Company by Halozyme Therapeutics, Inc. (NASDAQ: HALO) via a tender offer.  Under the terms of the merger agreement, the Company’s shareholders will receive $5.60 in cash for each share of Antares common stock owned.  The transaction is valued at $960 million.

Weiss Law is investigating whether (i) Antares’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $5.60 per-share merger consideration adequately compensates Antares’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.  Notably, the merger consideration is below the $6.50 median price target set by analysts, and at least one analyst set a price target for the Company of $8 per share, $2.40 above the per-share merger consideration.